Logo image of ORKA

ORUKA THERAPEUTICS INC (ORKA) Stock Fundamental Analysis

USA - NASDAQ:ORKA - US6876041087 - Common Stock

27.45 USD
-0.78 (-2.76%)
Last: 11/18/2025, 8:00:02 PM
27.45 USD
0 (0%)
After Hours: 11/18/2025, 8:00:02 PM
Fundamental Rating

3

ORKA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. ORKA has a great financial health rating, but its profitability evaluates not so good. ORKA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ORKA had negative earnings in the past year.
In the past year ORKA has reported a negative cash flow from operations.
ORKA had negative earnings in each of the past 5 years.
In the past 5 years ORKA always reported negative operating cash flow.
ORKA Yearly Net Income VS EBIT VS OCF VS FCFORKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ORKA's Return On Assets of -27.97% is fine compared to the rest of the industry. ORKA outperforms 69.42% of its industry peers.
ORKA has a better Return On Equity (-29.09%) than 78.05% of its industry peers.
Industry RankSector Rank
ROA -27.97%
ROE -29.09%
ROIC N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ORKA Yearly ROA, ROE, ROICORKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORKA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORKA Yearly Profit, Operating, Gross MarginsORKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ORKA has more shares outstanding
Compared to 5 years ago, ORKA has more shares outstanding
ORKA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORKA Yearly Shares OutstandingORKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ORKA Yearly Total Debt VS Total AssetsORKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 59.01 indicates that ORKA is not in any danger for bankruptcy at the moment.
The Altman-Z score of ORKA (59.01) is better than 97.37% of its industry peers.
ORKA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 59.01
ROIC/WACCN/A
WACCN/A
ORKA Yearly LT Debt VS Equity VS FCFORKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ORKA has a Current Ratio of 27.42. This indicates that ORKA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 27.42, ORKA belongs to the top of the industry, outperforming 97.19% of the companies in the same industry.
ORKA has a Quick Ratio of 27.42. This indicates that ORKA is financially healthy and has no problem in meeting its short term obligations.
ORKA has a Quick ratio of 27.42. This is amongst the best in the industry. ORKA outperforms 97.19% of its industry peers.
Industry RankSector Rank
Current Ratio 27.42
Quick Ratio 27.42
ORKA Yearly Current Assets VS Current LiabilitesORKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.06% over the past year.
EPS 1Y (TTM)55.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORKA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.13% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5Y14.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORKA Yearly Revenue VS EstimatesORKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 200M 400M 600M 800M 1B
ORKA Yearly EPS VS EstimatesORKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2024 2025 2026 2027 2028 2029 2030 2031 2032 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ORKA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORKA Price Earnings VS Forward Price EarningsORKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORKA Per share dataORKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ORKA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORUKA THERAPEUTICS INC

NASDAQ:ORKA (11/18/2025, 8:00:02 PM)

After market: 27.45 0 (0%)

27.45

-0.78 (-2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-04 2026-03-04
Inst Owners91.67%
Inst Owner Change33.62%
Ins Owners3.8%
Ins Owner Change0%
Market Cap1.33B
Revenue(TTM)N/A
Net Income(TTM)-99.98M
Analysts88.89
Price Target47.66 (73.62%)
Short Float %11.23%
Short Ratio10.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.23%
Min EPS beat(2)7.96%
Max EPS beat(2)22.5%
EPS beat(4)3
Avg EPS beat(4)-49.05%
Min EPS beat(4)-256.21%
Max EPS beat(4)29.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.29%
PT rev (3m)8.86%
EPS NQ rev (1m)-0.67%
EPS NQ rev (3m)-1.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.86
P/tB 3.86
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS7.1
TBVpS7.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.97%
ROE -29.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.42
Quick Ratio 27.42
Altman-Z 59.01
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)236.67%
Cap/Depr(5y)235.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5Y14.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-229.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1459.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1455.31%
OCF growth 3YN/A
OCF growth 5YN/A

ORUKA THERAPEUTICS INC / ORKA FAQ

What is the fundamental rating for ORKA stock?

ChartMill assigns a fundamental rating of 3 / 10 to ORKA.


What is the valuation status of ORUKA THERAPEUTICS INC (ORKA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORUKA THERAPEUTICS INC (ORKA). This can be considered as Overvalued.


What is the profitability of ORKA stock?

ORUKA THERAPEUTICS INC (ORKA) has a profitability rating of 1 / 10.